Innoveren Scientific Past Earnings Performance
Past criteria checks 0/6
Innoveren Scientific has been growing earnings at an average annual rate of 23.9%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 56.4% per year.
Key information
23.9%
Earnings growth rate
48.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -56.4% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Innoveren Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -3 | 2 | 0 |
| 30 Jun 23 | 0 | -5 | 2 | 0 |
| 31 Mar 23 | 0 | -8 | 3 | 0 |
| 31 Dec 22 | 0 | -10 | 3 | 0 |
| 30 Sep 22 | 1 | -10 | 3 | 0 |
| 30 Jun 22 | 1 | -8 | 4 | 0 |
| 31 Mar 22 | 2 | -7 | 6 | 0 |
| 31 Dec 21 | 2 | -5 | 6 | 0 |
| 30 Sep 21 | 2 | -6 | 7 | 0 |
| 30 Jun 21 | 2 | -1 | 7 | 0 |
| 31 Mar 21 | 2 | -6 | 6 | 0 |
| 31 Dec 20 | 2 | -7 | 7 | 1 |
| 30 Sep 20 | 4 | -26 | 8 | 1 |
| 30 Jun 20 | 6 | -33 | 12 | 1 |
| 31 Mar 20 | 8 | -32 | 17 | 1 |
| 31 Dec 19 | 8 | -33 | 19 | 0 |
| 30 Sep 19 | 8 | -14 | 19 | 0 |
| 30 Jun 19 | 6 | -13 | 15 | 0 |
| 31 Mar 19 | 6 | -8 | 10 | 0 |
| 31 Dec 18 | 8 | -4 | 9 | 0 |
Quality Earnings: IVRN is currently unprofitable.
Growing Profit Margin: IVRN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IVRN is unprofitable, but has reduced losses over the past 5 years at a rate of 23.9% per year.
Accelerating Growth: Unable to compare IVRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: IVRN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.